Can Psilocybin Help With Treatment-Resistant Depression? COMPASS Pathways Study Shows Promising Results

COMPASS Pathways plc (NASDAQ: CMPS), a mental health care company, presented positive data from the randomized, controlled, double-blind study of psilocybin therapy, at the American Psychiatric Association annual meeting in New Orleans. The study showed that a single 25mg dose of COMP360 psilocybin, in combination with psychological support, was associated with a highly statistically significant reduction in depressive symptoms after three weeks (p<0.001), with a rapid and durable response for up to 12 weeks.

The randomized, controlled, double-blind phase IIb clinical trial was designed to understand the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg in with treatment-resistant depression (TRD). 233 with TRD received either 1mg, 10mg or 25mg COMP360 psilocybin, in conjunction with psychological support from specially trained therapists. Symptoms of depression were assessed using the Montgomery-Åsberg depression rating scale (MADRS), a widely used and accepted scale for assessing depression; …

Full story available on Benzinga.com

More Can Psilocybin Help With Treatment-Resistant Depression? COMPASS Pathways Study Shows Promising Results